The topoisomerase I inhibitor SN38 arrests cell cycle progression primarily in S or G 2 phases of the cell cycle in a p53-independent manner. The Chk1 inhibitor, 7-hydroxystaurosporine (UCN-01), overcomes both S and G 2 arrest preferentially in cells mutated for p53, driving cells through a lethal mitosis and thereby enhancing cytotoxicity. The mechanism by which p53 maintains S and G 2 arrest was investigated here. The p53 wild-type MCF10A cells were arrested in S phase by incubation with SN38 for 24 h. Subsequent incubation with UCN-01 failed to abrogate arrest. To examine the impact of p53, MCF10A cells were developed, which express the tetramerization domain of p53 to inhibit endogenous p53 function. These cells were attenuated in SN38-mediated induction of p21
Introduction
DNA damage is a constant threat to the integrity of the human genome, and to protect against this threat, cells employ safeguard mechanisms called cell cycle checkpoints. These checkpoints are activated in response to DNA damage and trigger cell cycle arrest to allow time for repair of DNA lesions. Cells re-enter the cell cycle if the damage can be adequately repaired, or they die by apoptosis if the damage is too severe. This DNA damage-induced cytotoxicity is essential for therapeutic response to many anticancer drugs, but their efficacy may be limited by the damageactivated checkpoints. It was initially shown that the cytotoxicity of DNA damaging agents could be potentiated in cell culture systems by incubation with caffeine, which inhibited the protective cell cycle arrest at G 2 phase (Lau and Pardee, 1982; Schlegel and Pardee, 1986) . Subsequently, we discovered that 7-hydroxystaurosporine (UCN-01) was also capable of abrogating G 2 arrest, and was far more potent than caffeine (Bunch and Eastman, 1996; Wang et al., 1996) . Importantly, it was demonstrated that the ability to abrogate arrest and sensitize cells to DNA damaging agents is related to the p53 status of the cell; cells that express wild-type p53 are resistant to sensitization by checkpoint abrogators, whereas cells with defective p53 are sensitive (Fan et al., 1995; Powell et al., 1995; Russell et al., 1995; Shao et al., 1997) . The selectivity for p53-defective cells presents a potentially tumor-specific therapeutic strategy, whereby normal cells with wildtype p53 will be protected while p53-defective tumor cells will be killed.
Of tantamount importance to the development of such a therapeutic strategy is a firm understanding of the mechanisms by which p53 regulates cell cycle checkpoints. DNA damage-induced arrest in the G 1 phase of the cell cycle is dependent on the activation of the p53 tumor suppressor protein. In the absence of DNA damage, p53 is kept inactive by association with MDM2, an E3 ligase that targets p53 for ubiquitinmediated degradation (Haupt et al., 1997; Kubbutat et al., 1997) . When DNA is damaged, p53 becomes phosphorylated on the N-terminus by several damageactivated checkpoint proteins including ATM (on serine 15) and Chk2 (on serine 20) (Banin et al., 1998; Canman et al., 1998; Hirao et al., 2000; Shieh et al., 2000) . These phosphorylation events lead to dissociation of p53 from MDM2, promoting p53 stabilization and a consequent increase in abundance. p53 molecules then tetramerize, bind to p53-responsive elements, and induce transcription of the Cdk inhibitor p21 WAF1 , which arrests cell cycle progression (Xiong et al., 1993; Hengstschlager et al., 1999) .
In contrast to the G 1 checkpoint, DNA damageinduced S and G 2 checkpoints are triggered in a p53-independent manner. DNA damage causes rapid activation of ATM and/or ATR kinases, depending on the type of damage (reviewed in Sagata, 2002) . ATR and ATM subsequently phosphorylate and thereby activate the checkpoint kinases Chk1 and Chk2, respectively Zhao and PiwnicaWorms, 2001) . Chk1 and Chk2 then phosphorylate and inhibit Cdc25 phosphatases that are required for cell cycle progression. In the G 2 checkpoint, the critical target of Chk1 and Chk2 is Cdc25C, which normally activates Cdk1 to promote the onset of mitosis (Matsuoka et al., 1998; Zeng et al., 1998) . In S phase, the Cdc25A phosphatase is the critical target of Chk1 and/or Chk2; Cdc25A is degraded as a consequence of phosphorylation by these kinases, and this prevents the activation of Cdk2, a key mediator of S phase progression Falck et al., 2001; Zhao et al., 2002) .
In both S and G 2 , p53 can be activated in response to DNA damage and can protect against premature cell cycle progression induced by caffeine or UCN-01. The precise nature of this protection has not been fully investigated. To investigate the role of p53 signaling in the maintenance of S and G 2 checkpoints, we compared a p53 wild-type immortalized breast cell line, MCF10A, with newly generated sublines whose transactivation function was prevented by inhibition of tetramerization (MCF10A/EB and MCF10A/AL). This disruption was sufficient to make these cells susceptible to UCN-01-mediated abrogation of S phase arrest, but they remained resistant to abrogation of the G 2 checkpoint. This was attributed to retention of the p53 repressor function that suppresses many proteins including cyclin B. This was investigated further by the generation of MCF10A/Dp53 cells in which p53 expression was ablated by short hairpin RNA (shRNA). In these cells, transactivation of p21 WAF1 was blocked and cyclin B was elevated in G 2 phase in response to DNA damage. These cells underwent both S and G 2 checkpoint abrogation in response to UCN-01. Hence, both p53 transactivation and repression functions are important in full regulation of S and G 2 arrest and in protection from checkpoint inhibitors such as UCN-01.
Results

Stable transfection of MCF10A cells with the tetramerization domain of p53 inhibits p53-mediated transactivation of target genes
We have previously shown that the immortalized breast cell line MCF10A (p53 wild-type) arrests in S phase upon incubation with SN38, and this arrest cannot be abrogated by incubation with UCN-01 (Kohn et al., 2002) . It has been widely reported that the abrogation of cell cycle arrest and resultant chemosensitization achieved in certain cell types is related to their p53 status. To further explore whether the p53 pathway is the primary contributor to maintenance of S phase arrest in these cells, we created the MCF10A/EB cells, in which p53 signaling was interrupted by introduction of the tetramerization domain of p53 (see Materials and methods). This p53 fragment has been shown to function in a dominant-negative manner by binding to endogenous p53 and preventing the formation of tetramers that are required for transcriptional activation (Ossovskaya et al., 1996) . All the results with this cell line were subsequently confirmed in an independently derived subline, MCF10A/AL. Cells transfected with vector only exhibited identical phenotype to the MCF10A parent cells; as three different vectors were used in this paper without impact on the phenotype, results are only shown for the parental line.
The MCF10A, MCF10A/EB and MCF10A/AL cells were compared for their response to a 24-h incubation with SN38. We found that the three cell lines arrested at G 2 at low concentrations of SN38, and in late-, mid-, or early S phase at higher concentrations (Figure 1) . Lysates from the cells were then examined for the status of cell cycle checkpoint proteins (Figure 2 ). The p53 protein was detectable in the MCF10A, MCF10A/ EB and MCF10A/AL cells, and was elevated in damaged cells. Importantly, DNA damage markedly elevated phosphorylation of p53 on serines 15 and 20 in the three cell lines. The cyclin-dependent kinase inhibitor p21 WAF1 , a well-known p53 target gene, was strongly induced in the MCF10A cells in response to DNA damage; however, little p21 WAF1 induction was observed in the MCF10A/EB or MCF10A/AL cells except at the highest concentration of SN38. This demonstrates that the ability of p53 to transactivate target genes in response to DNA damage is greatly impaired in these cells. We also compared other checkpoint proteins in the two cell lines. Chk1 was repressed at concentrations of SN38 that activated p53 in all three cell lines, which is consistent with a recent report that Chk1 can be repressed in a p53-dependent manner (Damia et al., 2001) . This suggests that the p53 repressor function remains intact in these cells. Chk1 was also phosphorylated in the three cell lines, although the phosphorylation was attenuated at the highest concentration of SN38 presumably as a consequence of the reduction in Chk1 protein.
Chk2 was also phosphorylated in response to DNA damage, and was detected as a band shift with antibodies to both total and threonine-68-phosphorylated protein; the upper band is likely the hyperphosphorylated, active form of the kinase. Further analysis demonstrated that Chk2 was also phosphorylated at serine 516, a site of autophosphorylation (Schwarz et al., 2003) confirming that the kinase is activated. When active, Chk1 and Chk2 phosphorylate Cdc25A leading to its degradation and this was evident at concentrations of SN38 that arrested cells in S phase. Cyclin E also accumulated in S phasearrested cells, which is an indication of the inhibition of Cdk2 which, when active, targets cyclin E for degradation. Figure 1 The impact of SN38 on cell cycle arrest in MCF10A, MCF10A/EB, MCF10A/AL, and MCF10A/Dp53 cells. Cells were incubated with 0-30 ng/ml SN38 for 24 h. Cells were harvested and assayed for DNA content by flow cytometry Figure 2 The impact of SN38 on checkpoint-regulatory proteins in MCF10A, MCF10A/EB, MCF10A/AL, and MCF10A/Dp53 cells. Cells were incubated with 0-30 ng/ml SN38 for 24 h. Cells were harvested and lysates were analysed by Western blotting with the indicated antibodies p53-mediated repression of S and G 2 checkpoint abrogation AA Levesque et al
UCN-01 abrogates SN38-induced S phase arrest in MCF10A/EB and MCF10A/AL cells
Having established that the transactivation function of p53 had been inhibited in MCF10A/EB and MCF10A/ AL cells, we next investigated the impact of this interruption on the ability of UCN-01 to abrogate SN38-induced S and G 2 arrest. Cells were first arrested in S phase by a 24-h incubation with SN38, at which time SN38 was removed and UCN-01 added. Flow cytometric analysis of MCF10A cells showed no abrogation of S or G 2 arrest after 6 or 24 h of incubation with UCN-01 ( Figure 3 ). In contrast, MCF10A/EB and MCF10A/AL cells incubated with 15 nM UCN-01 showed clear abrogation of S phase arrest by 6 h, but there was no abrogation of G 2 arrest at 24 h. Under similar conditions, p53-defective MDA-MB-231 cells had abrogated G 2 arrest and undergone a lethal mitosis (Kohn et al., 2002) . It is also interesting that even in the absence of UCN-01, MCF10A/EB and MCF10A/AL, cells were able to progress to G 2 within 24 h of removal of SN38, suggesting that they have a reduced ability to remain arrested in S phase. Analysis of cell cycle proteins was then performed in cells incubated with UCN-01. Consistent with data shown in Figure 2 , incubation with SN38 induced phosphorylation of Chk1 and Chk2, loss of Cdc25A and accumulation of cyclin E (Figure 4 ). Upon addition of UCN-01 to MCF10A cells, Cdc25A did not reaccumulate and cyclin E was not degraded consistent with the sustained S phase arrest in these cells. In contrast, the MCF10A/EB and MCF10A/AL cells reaccumulated Cdc25A within 1 h of addition of UCN-01 and degraded cyclin E over 3-6 h. These observations are consistent with abrogation of S phase arrest as observed in the p53 mutant MDA-MB-231 cells, which also abrogate S phase arrest (Kohn and Eastman, unpublished observations) . Both Cdc25A and Cdc25C become hyperphosphorylated as cells enter mitosis, and this would be observed as a band with retarded electrophoretic mobility, but no such band was detected consistent with these cells remaining arrested in G 2 . These data support the idea that p53-mediated transactivation of target genes such as p21 WAF1 is critical for protection against UCN-01-mediated abrogation of S phase arrest.
Arrest in G 2 correlates with suppression of cyclin B in MCF10A/EB and MCF10A/AL cells
The failure of UCN-01-treated MCF10A/EB and MCF10A/AL cells to progress through G 2 and undergo a lethal mitosis was in contrast to what we have seen in the p53 mutant cell line MDA-MB-231 (Kohn et al., 2002) . This indicates that, although interruption of p53 transactivation appears sufficient to permit abrogation of S phase arrest, there appear to be additional processes Figure 3 The impact of p53 disruption on UCN-01-mediated abrogation of S and G 2 arrest. (a) MCF10A cells, and (b-d) their isogenic derivatives, were incubated with 10 ng/ml SN38 for 24 h; media was removed, and fresh media with or without 15 nM UCN-01 was added for an additional 6 or 24 h. Cells were harvested at the indicated times and DNA content was assessed by flow cytometry p53-mediated repression of S and G 2 checkpoint abrogation AA Levesque et al that inhibit passage through G 2 . In addition to functioning as a transactivator, p53 can also function as a repressor, inhibiting transcription of genes required for cell cycle progression such as cyclins A and B. This provides a second mechanism, in addition to transactivation of p21 WAF1 , by which p53 can inhibit Cdk1 activity to prevent premature entry into mitosis. We have reported previously that incubation of MCF10A cells with SN38 causes a marked suppression of cyclins A and B, whereas the p53-defective MDA-MB-231 cells demonstrated elevation of these cyclins in response to SN38 (Kohn et al., 2002) . Results presented in Figure 2 showed that another p53-responsive gene, Chk1, was repressed in the three MCF10A cell lines at the higher concentrations of SN38. To better define the role of p53-mediated repression in cell cycle regulation, we investigated the levels of cyclin B (Figure 5a ). As seen with Chk1, the higher concentrations of SN38 led to reduced levels of cyclin B. However, at lower concentrations, there was an increase in cyclin B, which is likely a consequence of an increased number of cells in G 2 , the phase at which cyclin B is normally highest.
Western blotting of total cell populations does not permit analysis of the heterogeneity of response at different phases of the cell cycle. To better define the levels of cyclin B in each phase of the cell cycle, we used two-dimensional flow cytometry (Figure 5b) . At low concentrations of SN38, cells accumulated in G 2 , but the level of expression of cyclin B on a per cell basis was not markedly increased; the larger proportion of cells with cyclin B is consistent with the elevated cyclin B observed in Western blots. At higher concentrations of SN38, there was a clearly defined population of cells with little or no expression of cyclin B; this represented the majority of the cells at the highest concentration. This repression of cyclin B was observed in the MCF10A cells, and the two derivatives MCF10A/EB and MCF10A/AL.
The results in Figure 5 were obtained after a 24-h incubation with SN38. To further investigate the contribution of p53-mediated repression to checkpoint abrogation, we removed SN38 and incubated the cells in UCN-01 for 9 h to let the MCF10A/EB and MCF10A/ AL cells progress to G 2 ; during this time frame, the majority of parental MCF10A cells remained arrested in S phase ( Figure 6 ). All three cell lines showed a further decrease in the proportion of cells expressing cyclin B but, importantly, it can be seen that the MCF10A/EB and MCF10A/AL cells arrested in S phase with repressed cyclin B were still driven into G 2 by UCN-01, suggesting that p53-mediated repression does not prevent abrogation of S phase arrest. We hypothesize that this cyclin B repression indicates that the transactivator and repressor functions of p53 are separable, and in creating the MCF10A/EB and MCF10A/AL cell lines, we have attenuated only the transactivator function, leaving the repressor function intact.
Generation of an MCF/10A cell line that lacks p53 protein expression
In order to explore further whether the phenotype seen in the MCF10A/EB and MCF10A/AL cells was due to selective inhibition of the transactivation function of p53, we ablated p53 signaling completely by transfecting MCF10A cells with a vector expressing shRNA against p53. These cells, termed MCF10A/Dp53, were incubated with different concentrations of SN38 and cell cycle analysis was performed. Similar to observations in the MCF10A cells, low concentrations of SN38 caused primarily a G 2 arrest, while higher concentrations arrested cells in late-, mid-, or early S phase (Figure 1) .
We next examined cell lysates for expression and activation of the various checkpoint regulatory proteins (Figure 2) . Expression of p53 and p21 WAF1 was undetectable in MCF10A/Dp53 cells, confirming inhibition of p53-mediated transactivation. SN38 induced phosphorylation of both Chk1 and Chk2 proteins but, unlike the other MCF10A cell lines, Chk1 was not downregulated at high concentrations suggesting that the MCF10A/Dp53 cells have lost the p53-mediated repressor function. Like the other MCF10A lines, Cdc25A was degraded at concentrations above 1 ng/ ml, and cyclin E levels accumulated.
We next asked whether MCF10A/Dp53 cells suppressed cyclin B in the face of DNA damage. At Figure 4 Analysis of cell cycle checkpoint-regulatory proteins in MCF10A cells and their isogenic derivatives incubated with UCN-01. The indicated cells were incubated with 10 ng/ml SN38 for 24 h; media was removed, and fresh media containing 15 nM UCN-01 was added for an additional 1-15 h. Cells were harvested at the indicated times and lysates were analysed by Western blotting with the indicated antibodies. The upper bands in the last two lanes represent the hyperphosphorylated forms of Cdc25A and Cdc25C p53-mediated repression of S and G 2 checkpoint abrogation AA Levesque et al concentrations of SN38 that arrested these cells in S phase, there was no repression of cyclin B detected by Western analysis while two-dimensional flow cytometry showed that the majority of cells in both S and G 2 accumulated cyclin B ( Figure 5 ). This reinforces the conclusion that p53 is responsible for cyclin B suppression in the face of DNA damage, and therefore that p53 repressor function is still present in the MCF10A/EB and MCF10A/AL cells.
MCF10A/Dp53 cells are sensitive to UCN-01-mediated abrogation of S and G 2 arrest
Having confirmed the knockdown of p53 expression and consequent accumulation of cyclin B in the MCF10A/ Dp53 cells, we investigated the impact on S and G 2 checkpoint integrity in the face of UCN-01. The cells were incubated with SN38 for 24 h to generate an S phase arrest, and then incubated with 15 nM UCN-01 over a 24-h time course. The cells rapidly abrogated S phase arrest in the presence, but not absence, of UCN-01, moving rapidly to G 2 within 6 h of addition of UCN-01 (Figure 3) . Additionally, and of particular interest, these cells also progressed through mitosis by 24 h, and the majority of cells were found to be in either G 1 or with sub-G 1 DNA content indicative of dead or dying cells. This is in contrast to the observations with the MCF10A/EB and MCF10A/AL cells, which abrogated S phase arrest but did not pass through G 2 and remained viable. Furthermore, the MCF10A/Dp53 cells retained elevated cyclin B after incubation with UCN-01 that would facilitate passage through mitosis ( Figure 6 ). Analysis of cell cycle proteins was then performed. The MCF10A/Dp53 cells demonstrated protein changes consistent with abrogation of arrest. Reaccumulation of Cdc25A was observed within 1 h of addition of UCN-01, and cyclin E was degraded over 3-6 h after addition of UCN-01 (Figure 4 ). These observations are very similar to the results observed in the MCF10A/EB and MCF10/AL cells. However, at 12-15 h, both Cdc25A and Cdc25C showed hyperphosphorylated forms that are indicative of entry into mitosis. This is consistent with the cell cycle analyses that demonstrated passage through mitosis by 24 h after addition of UCN-01. Together, these data indicate that inhibition of p53 expression is sufficient to allow UCN-01-mediated abrogation of both S and G 2 phase arrest induced by SN38. Analysis of cyclin B expression during incubation of (a) MCF10A and (b-d) its isogenic derivatives with UCN-01. Cells were incubated with 10 ng/ml SN38 for 24 h, media was removed and fresh media with or without 15 nM UCN-01 was added for 9 h, to analyse cells just prior to their potential entry into mitosis. Cells were harvested after the indicated times and treatments, fixed, incubated with FITC-conjugated anti-cyclin B and propidium iodide and analysed by two-dimensional flow cytometry. The numbers in each panel represent the percent of cells in each quadrant of the distribution p53-mediated repression of S and G 2 checkpoint abrogation AA Levesque et al
Discussion
A major focus in cancer research in recent years has been the identification and characterization of molecular differences between normal and tumor cells, with the goal of developing molecularly targeted therapies that kill only the cells harboring the tumor-specific alterations. The tumor suppressor p53 is the most commonly mutated gene in human cancers, and is therefore an attractive target for the development of anticancer therapies. The loss of p53 has been associated with resistance to apoptosis, and this has led to numerous efforts to reintroduce p53 into tumor cells. This idea is somewhat confounding as p53 also causes G 1 arrest, which protects cells from the cytotoxicity that can result from DNA damage. Although not required for S or G 2 arrest, p53 reinforces these checkpoints. Hence, p53 can also protect cells from aberrant progression through S, G 2 and mitosis. Evidence that p53 can protect cells from DNA damage has been further substantiated by the discovery of checkpoint inhibitors such as UCN-01 and Go¨6976, which can overcome S and G 2 arrest selectively in cells with nonfunctional p53 and drive these cells through a lethal mitosis, thereby enhancing cytotoxicity (Shao et al., 1997; Kohn et al., 2002 Kohn et al., , 2003 . What has not been described previously is the precise role of p53 in reinforcing the S and G 2 checkpoints. We found previously that incubation of S phasearrested MDA-MB-231 cells (p53 mutant) with UCN-01 drives cells from S phase to G 2 in 6 h, and then through a lethal mitosis (Kohn et al., 2002) . Similar studies performed in the p53 wild-type cell line MCF10A showed that SN38 also caused an S phase arrest, but subsequent treatment with UCN-01 did not cause abrogation of arrest (Kohn et al., 2002 ). In the current study, we directed attention to the mechanism by which S phase arrest was maintained in p53 wild-type cells, with particular attention given to the function of p53 in this process. To explore this, we first generated a cell line that expressed an inhibitor of p53 tetramerization, the functional form of p53 that binds to DNA response elements and transactivates target gene transcription. In comparing the MCF10A cells to the MCF10A/EB cells (and subsequently the MCF10A/AL cells), we found that the latter cells were clearly inhibited in their p53-transcriptional activation function because p21 WAF1 induction was attenuated in these cells. This inhibition of p53 was sufficient to allow UCN-01-mediated abrogation of S phase arrest.
S phase arrest was associated with loss of Cdc25A and accumulation of cyclin E in all the cell lines studied here. This occurs because DNA damage activates Chk1 that phosphorylates Cdc25A, thereby targeting it for degradation . Cells lacking Cdc25A cannot activate Cdk2, which normally phosphorylates cyclin E leading to its destruction, and hence cyclin E accumulates. In the MCF10A/EB cells, abrogation of S phase arrest was associated with reaccumulation of Cdc25A consistent with UCN-01-mediated inhibition of Chk1. Similar events occur in the p53-defective MDA-MB-231 cell line (data not shown) demonstrating that the loss of Cdc25A is not due to p53-mediated repression. However, in MCF10A cells, UCN-01 failed to induce reaccumulation of Cdc25A suggesting that the transactivation function of p53 may also regulate Cdc25A. It is known that transcription of Cdc25A can be regulated by both c-Myc and E2F, both of which can in turn be suppressed by p21 WAF1 (Vigo et al., 1999; Kitaura et al., 2000; Santoni-rugiu et al., 2000) . Therefore, in addition to inhibiting Cdk2 activity, p21 WAF1 may also prevent S phase progression by downregulating Cdc25A transcription.
Perhaps the most intriguing observation in the MCF10A/EB cells was that, despite the ability of UCN-01 to induce S phase progression, these cells arrested again in G 2 where they were resistant to the continued presence of UCN-01. The p53-mediated G 2 arrest has been shown to be partially dependent upon inhibition of Cdk1/cyclin B by p21 WAF1 (Flatt et al., 2000) , but the studies presented here indicate that ablation of p21 WAF1 transactivation is not sufficient to allow abrogation of G 2 arrest. In addition to being a transactivator, p53 is also a repressor of the transcription of certain genes required for cell cycle progression. In response to DNA damage, p53 has been reported to repress several genes required for entry into mitosis, including Cdk1, its regulatory subunit cyclin B, and cyclin A (Flatt et al., 2000; Park et al., 2000; Manni et al., 2001) . This may provide an additional mechanism by which p53 guards against premature entry into mitosis. A comparison of MCF10A and MCF10A/EB cells shows that cyclin B was suppressed in both cell lines in S phase-arrested cells; cyclin B was further repressed after the cells had been induced by UCN-01 to progress to G 2 . Although not assessed in this study, it is likely that cyclin A is also repressed in these cells (Kohn et al., 2002) . We therefore deduced that persistent repression of cyclins A and B, and perhaps of other proteins, could be the explanation for the G 2 arrest.
To investigate these questions further, we generated an MCF10A cell line in which p53 expression was ablated using shRNA (MCF10A/Dp53) and compared it to the other cell lines with respect to cell cycle arrest and abrogation. These cells all behaved similarly in that they arrested in S phase in response to SN38. However, the MCF10A/Dp53 cells were able to abrogate arrest upon incubation with UCN-01, progressing through both S and G 2 phases by 24 h after addition of UCN-01. Importantly, cyclin B was no longer repressed in S and G 2 phases in these cells. We therefore conclude that persistent p53-mediated suppression of proteins such as cyclin B in MCF10A/EB and MCF10A/AL cells is the mechanism by which these cells maintain G 2 arrest when incubated with UCN-01.
The experiments with the MCF10A/Dp53 cells confirm the ability of p53 to repress cyclin B and highlight the fact that the MCF10A/EB and MCF10A/AL cells still suppress cyclin B despite inhibition of p53 tetramerization. These observations are not unique to the MCF10A cell lines, as we have performed similar experiments in an immortalized mammary epithelial cell line (IMEC); we have observed that expression of the p53-mediated repression of S and G 2 checkpoint abrogation AA Levesque et al tetramerization domain can lead to a similar phenotype as that seen in MCF10A/EB cells, while expression of shRNA permits abrogation of both S and G 2 arrest (data not shown). Consequently, we conclude that p53 repressor function must still be intact in cells expressing the tetramerization domain. This raises intriguing questions about the mechanism of interruption of p53 signaling by the transfected p53 fragment, and also about mechanisms of repression by p53. If the transfected fragment prevents the ability of endogenous p53 to form tetramers, then these data suggest that tetramerization is not required for p53-mediated repression of cyclin B. p53 has been shown to repress numerous genes, but this repression usually requires sequence-specific binding of tetrameric p53 (reviewed in Ho and Benchimol, 2003) . However, it is likely that different mechanisms of repression are employed for different genes; the transfected p53 fragment may therefore prevent repression of some genes, but not others. Several mechanisms of repression by p53 exist, including interference with transcriptional activators, interference with the basal transcriptional machinery, and interaction with chromatin-remodeling proteins at the target gene promoters. A novel mechanism of suppression has additionally been proposed in which p53 binds to an atypical site in the promoter of repressed genes (Johnson et al., 2001) . The normal p53 binding site consists of two short head-to-head consensus sequences separated by 0-13 nucleotides. In contrast, the MDR1 gene was found to contain two adjacent head-to-tail sequences which, when replaced with the consensus head-to-head orientation of this regulatory element, converted the promoter from being transcriptionally repressed by p53 to being transcriptionally activated. Similar head-to-tail p53 binding sites have been identified in the cyclin A and cyclin B promoters, and could potentially provide an explanation for the mechanism of p53 repression of these genes (Johnson et al., 2001) . Importantly, the head-to-tail orientation of this binding site would not appear to accommodate tetrameric (normal) binding of p53, but might still be able to bind monomeric or dimeric forms of p53 that can still occur in MCF10A/EB cells. The results presented here also demonstrated that Chk1 was repressed in a p53-dependent manner. A survey of the Chk1 promoter sequence identified a similar head-tohead element (GGGCAGGACA) 560 base pairs upstream of the transcription start site. However, in this case the site was not duplicated as in MDR1 or cyclin B. Such a site would certainly be unable to accommodate a p53 tetramer, but it remains to be determined whether this sequence is responsible for repression of Chk1.
Our observations here indicate that the p53 transactivation function can be inhibited, leaving the repressor function intact, by expression of the p53 tetramerization domain, and that this is sufficient to overcome p53-mediated maintenance of the S phase checkpoint. Abrogation of the G 2 checkpoint additionally requires disruption of the repressor function of p53, which we accomplished by inhibiting p53 expression directly using shRNA. As the G 2 checkpoint is the final opportunity for a cell to repair damage before entering mitosis, it is logical that the G 2 checkpoint should have the most substantial mechanism to prevent further progression through the cell cycle. We have demonstrated here that the different mechanisms of disruption of p53 signaling yield somewhat different consequences; these studies reveal the direct role of p53-mediated activities in the maintenance of both the S and G 2 checkpoints, but also emphasize that the specific actions of p53 in the S and G 2 phases are different and separable.
These results may also help to explain why a few investigators have failed to observe selectivity of UCN-01 for p53-defective cells (Husain et al., 1997; Hirose et al., 2001) . It is essential to establish that, under the particular conditions used, the p53-dependent checkpoint has been fully activated by DNA damage, and this involves both transactivation and repression functions. For example, there is evidence that cyclin B expression can be dysregulated in a much higher proportion of tumors than are defective for p53 (Gorczyca et al., 1997) . Hence, additional defects in the pathways may weaken the protective checkpoint. In this regard, it is important to note the use of nontransformed cells in the current studies. These cells more closely reflect the normal cells in the patient that it is hoped will be protected from checkpoint inhibitors by their wild-type p53 status. Hence, the therapeutic combination of a DNA damaging agent plus a checkpoint inhibitor may be effective not only against p53-defective tumors but also against some p53 wild-type tumors that have other defects in checkpoint pathways, but it will spare normal cells that lack these defects.
Materials and methods
Chemicals
SN38, the active metabolite of the topoisomerase I inhibitor irinotecan, was kindly provided by Dr J Patrick McGovren (Pharmacia Upjohn Inc. Kalamazoo, MI, USA). UCN-01 was kindly provided by Dr Edward Sausville (National Cancer Institute, Bethesda, MD, USA). Cells were incubated with SN38 for 24 h, after which the drug was removed and the cells were incubated in fresh medium with or without the addition of UCN-01 for up to an additional 24 h.
Cell culture
The p53 wild-type breast cell line MCF10A (American Type Culture Collection, Manassas, VA, USA) was maintained in DMEM/F12 media supplemented with 10% fetal bovine serum, penicillin (100 U/ml) streptomycin (100 mg/ml) and fungizone (0.25 mg/ml), 8 mg/ml insulin, 20 ng/ml epidermal growth factor and 500 ng/ml hydrocortisone.
Inhibition of p53 was accomplished by expressing amino acids 276-369 of human p53 derived from the tetramerization domain and shown previously with the equivalent rat sequence to suppress p53 activity (Ossovskaya et al., 1996) . The required cDNA sequence was amplified by PCR, flanked with Kpn1 and Xho1 restriction sites and cloned into pcDNA3.1 þ (Invitrogen). The plasmid was transfected into MCF10A cells, selected for G418 resistance, and the clone used in these studies was termed MCF10A/EB. The same fragment of p53, but cloned p53-mediated repression of S and G 2 checkpoint abrogation AA Levesque et al into pcDNA3.1/Myc-HisA (Invitrogen), was obtained from Dr Michael Spinella (Dartmouth Medical School) (Curtin et al., 2001) , and used to generate an independent derivative termed MCF10A/AL. The MCF10A cells were also transfected with pcDNA3.1 plus or minus pSuper-p53 (Oligoengine, Seattle, WA, USA) and selected in G418, the resulting cell line was termed MCF10A/Dp53. These selection antibiotics were removed before all experimental treatments.
Cell cycle analysis
Cell cycle analysis was performed as described previously, whereby cells are harvested, fixed in ethanol, incubated with ribonuclease and stained with propidium iodide (Demarcq et al., 1994) . DNA content was then determined on a Becton Dickinson FACScan flow cytometer. Results are expressed as histograms because modeling programs, although good for displaying the number of cells in either G 1 , S or G 2 , do not adequately display the progression through S phase (i.e. discriminate early S, mid-S and late S phase). Expression of cyclin B was assessed by incubating ethanol-fixed cells with FITC-conjugated anti-cyclin B antibody (Pharmingen, San Diego, CA, USA) prior to addition of ribonuclease and propidium iodide.
Immunoblotting
For immunoblot analysis, cells were rinsed with phosphatebuffered saline, and then lysed by direct addition of Laemmli sample buffer. Samples were immediately boiled for 5 min and stored at À201C. Proteins were separated by SDS-PAGE (8 or 10%) and transferred onto polyvinylidene difluoride membranes. Membranes were blocked with 5% non-fat milk in Tris-buffered saline, 0.1% Tween 20, and then probed with the appropriate antibody overnight at 41C (Chk1, Cdc25A, Cdc25C, cyclin E, cyclin B, p53, p21
WAF1
, Santa Cruz; phosphoserine-345-Chk1, phosphothreonine-68-Chk2, phosphoserine-516-Chk2, phosphoserine-15-p53, phosphoserine-20-p53, Cell Signaling; Chk2, Upstate). Subsequently, membranes were washed in Tris buffered saline, 0.1% Tween 20, and incubated with secondary antibody conjugated to horseradish peroxidase (BioRad). Proteins were visualized by enhanced chemiluminescence (Amersham).
Dedication
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